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Abstract
Background: Patients diagnosed with lung adenocarcinoma (AD) and squamous cell carcinoma
(SCC), two major histologic subtypes of lung cancer, currently receive similar standard treatments,
but resistance to adjuvant chemotherapy is prevalent. Identification of differentially expressed
genes marking AD and SCC may prove to be of diagnostic value and help unravel molecular basis
of their histogenesis and biologies, and deliver more effective and specific systemic therapy.
Methods: MiRNA target genes were predicted by union of miRanda, TargetScan, and PicTar,
followed by screening for matched gene symbols in NCBI human sequences and Gene Ontology
(GO) terms using the PANTHER database that was also used for analyzing the significance of
biological processes and pathways within each ontology term. Microarray data were extracted
from Gene Expression Omnibus repository, and tumor subtype prediction by gene expression
used Prediction Analysis of Microarrays.
Results: Computationally predicted target genes of three microRNAs, miR-34b/34c/449, that
were detected in human lung, testis, and fallopian tubes but not in other normal tissues, were
filtered by representation of GO terms and their ability to classify lung cancer subtypes, followed
by a meta-analysis of microarray data to classify AD and SCC. Expression of a minimal set of 17
predicted miR-34b/34c/449 target genes derived from the developmental process GO category
was identified from a training set to classify 41 AD and 17 SCC, and correctly predicted in average
87% of 354 AD and 82% of 282 SCC specimens from total 9 independent published datasets. The
accuracy of prediction still remains comparable when classifying 103 AD and 79 SCC samples from
another 4 published datasets that have only 14 to 16 of the 17 genes available for prediction (84%
and 85% for AD and SCC, respectively). Expression of this signature in two published datasets of
epithelial cells obtained at bronchoscopy from cigarette smokers, if combined with cytopathology
of the cells, yielded 89–90% sensitivity of lung cancer detection and 87–90% negative predictive
value to non-cancer patients.
Conclusion: This study focuses on predicted targets of three lung-enriched miRNAs, compares
their expression patterns in lung cancer by their GO terms, and identifies a minimal set of genes
differentially expressed in AD and SCC, followed by validating this gene signature in multiple
published datasets. Expression of this gene signature in bronchial epithelial cells of cigarette
smokers also has a great sensitivity to predict the patients having lung cancer if combined with
cytopathology of the cells.
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Background
Lung cancer is the most common cause of cancer mortal-
ity in the world [1], and over 50% of the cases are diag-
nosed as AD and SCC. These two subtypes present unique
histopathological characteristics at distinctive preferential
anatomic locations, and yet are classified together as non-
small cell lung cancer (NSCLC) and their staging and
treatment are similar. Standard treatment strategies
include surgical resection, followed by radiation and/or
chemotherapy. Chemotherapy, especially for advance-
stage disease, is usually palliative rather than curative due
to resistance [2], so more effective systemic therapy is in
urgent need. One solution might be developing novel
agents to target specific pathways in different tumor sub-
types [3]. Gene expression signatures that can characterize
the heterogeneity of lung cancer would provide molecular
underpinnings of the histopathological features and the
regulatory networks for tumor subtypes and lead to iden-
tification of molecular targets for such agents [4].
Late diagnosis of extensive diseases is the main reason for
treatment failure in lung cancer. Although a recent large
randomized study suggested that computed tomography
screening may not decrease number of diagnosis of
advanced lung cancer and death from the tumor [5], early
detection may still be a key to improve survival of early-
stage patients, particularly if more sensitive and specific
diagnostic tools can be developed. Abnormal radio-
graphic imaging requires further examination such as
bronchoscopy or biopsy, but these procedures are highly
variable in diagnostic yield and not very sensitive to small
peripheral tumors (only 30~40% in accuracy) [6]. It will
be cost efficient for clinical management if evaluation of
specific gene signature in specimens taken by bronchos-
copy could eliminate false-positive cases to reduce subse-
quent unnecessary tests and treatments [7].
MicroRNAs (miRNAs) are a group of small non-protein
coding RNAs that often demonstrate temporally or spa-
tially restricted expression patterns, and have great poten-
tial to mark the cytological and histological origins of
tissues with less clear differentiated phenotypes, such as
poorly differentiated tumors [8]. In our previous report,
expression of 345 miRNAs was profiled in 40 normal
human tissue types, providing a reference in abundance
for identification of tissue-specific or tissue-enriched miR-
NAs [9]. It is believed that miRNAs post-transcriptionally
regulate gene expression through at least two mecha-
nisms: translational inhibition or degradation of mRNAs.
Therefore, functional roles of a miRNA should be deter-
mined by its target genes. It has been shown that many tis-
sue-specific factors have reduced expression in cancers
derived from the tissues in which these factors are specifi-
cally expressed [10,11]. For tissue-specific miRNAs that
are under-expressed in the neoplastic tissue counterparts,
deregulation of their target genes in these disease lesions
would likely characterize the pathobiology of the tumor.
Current identification of miRNA targets mainly follows
computational prediction, and only a handful of them
have been experimentally verified. Many investigations
presumed expression of miRNA is opposite to that of their
targets, based on observations in which transfecting miR-
NAs into human cells down-regulated large number of
target mRNAs [12]. A major drawback of this strategy is its
lack of considering target genes whose protein but not
transcript levels are down regulated by the miRNAs. In
fact, a recent report using biochemical purification
showed that, among the genes co-immunoprecipitated
with the RNA-induced silencing complex after the miRNA
transfection, about 70% of them have no change in
mRNA abundance but their 3'-end untranslated regions
actually mediate reduced protein expression of a reporter
gene in response to transfection of the same miRNA [13].
In this study, expression of all predicted target genes of
three lung-enriched miRNAs was examined in different
subtypes of lung cancer without relating to matched
miRNA expression. After a series of data filtering by classi-
fication of tumor subtypes, a minimal gene signature was
identified to correctly predict the majority of AD and SCC
cases from multiple published datasets. Expression of the
same signature was also examined in two airway epithelial
cell gene expression datasets to evaluate its diagnostic
value for early detection of lung cancer in cigarette smok-
ers.
Methods
Prediction and filtering of miRNA target genes
In general, the union of combining different prediction
algorithms gives much greater number of predicted
miRNA target genes, and therefore less false negatives and
more false positives, than individual algorithms or the
intersection of combining different algorithms. The strat-
egy used in this study was to obtain maximally possible
number of candidates, followed by a series of data reduc-
tion to filter out genes. MiRNA target genes were predicted
by union of miRBase Target v4 (powered by miRanda),
TargetScan 4.0, and PicTar, followed by screening for
availability of gene symbols in NCBI human sequences
and Gene Ontology (GO) terms using the PANTHER data-
base v6 [14]. Genes with eligible symbols available and
being categorized by GO terms were retained. The number
of genes in each category within the Biological Processes
Ontology term and representation of each category were
examined: developmental processes, nucleotide metabo-
lism, and signal transduction are the top three categories
with the largest number of genes and the smallest cor-
rected p values (see below). PANTHER was also used forB
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Table 1: Summary of lung cancer datasets used in this study.
Database GEO Platform Institute PMID Technology 
type
Organism AD# SCC# Stage # Genes % Correct AD % Correct 
SCC
1 GSE3398 GPL2648/2778/
2832
Stanford 11707590 spotted cDNA Human 41 17 I to III 17 93 94
2 NA* Affy HG-U95A DFCI 11707567 oligonucleotide Human 139 21 I to III 17 91 86
3 NA** Affy HG-
U133A
U Michigan 12118244 oligonucleotide Human 86 0 I to III 17 95 NA
4 GSE3141 Affy U95A/
HuGeneFL
Duke 16899777 oligonucleotide Human 54 57 I to III 17 83 72
5 GSE4573 Affy HG-
U133A
U Michigan 16885343 oligonucleotide Human 0 129 I to III 17 NA 85
6 GSE1037 CHUGAI 41K CIH, Japan 15016488 spotted cDNA Human 12 0 NA 17 83 NA
7 GSE6253 Affy HG-U95A/
U133AB
Washington U 17194181 oligonucleotide Human 14 36 I 17 79 78
8 GSE3268 Affy HG-
U133A
UC Davis 16188928 oligonucleotide Human 0 5 NA 17 NA 100
9 GSE1987 Affy HG-U95A Tel Aviv U NA oligonucleotide Human 8 17 I to III 17 88 59
10 GSE6044 Affy HG-Focus U Duesseldorf, 
Germany
NA oligonucleotide Human 10 10 NA 16 70 90
11 GSE7880 Affy HG-Focus Heinrich-Heine 
U, Germany
NA oligonucleotide Human 25 18 IIIB/IV 16 92 83
12 GSE2514 Affy HG-U95A U Colorado 16314486 oligonucleotide Human 20 0 NA 15 100 NA
13 GSE5843 
GSE5123
PC Human 
Operon v2
Prince Charles 
H, Australia
17082175 
17504995
oligonucleotide Human 48 51 I to III 14 75 80
14 GSE2514 Affy MG-U74A U Colorado 16314486 oligonucleotide Mouse 44 0 NA 13 100 NA
* http://www.broad.mit.edu/cgi-bin/cancer/datasets.cgi
** https://caarraydb.nci.nih.gov/caarray/publicExperimentDetailAction.do?expId=1015897558050283BMC Medical Genomics 2008, 1:61 http://www.biomedcentral.com/1755-8794/1/61
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analyzing the significance of biological processes and
pathways within each ontology term.
Extraction of microarray data from public databases
Microarray data were extracted from Gene Expression
Omnibus repository, and all databases used in this study
were summarized in Table 1. To comply with the Consol-
idated Standards of Reporting Trials statement [15], selec-
tion of databases using human specimens investigated in
this study and the key findings are summarized in the
Additional file 1 and the flow diagram for the rationale of
database selection is summarized in Figure 1. All microar-
ray datasets from Gene Expression Omnibus using human
primary lung cancer specimens (no cell lines) under the
search terms "human lung adenocarcinoma" or "human
lung squamous carcinoma" as of July 1st, 2007 were
reviewed. Only one dataset, GSE7339, was removed from
further analysis due to too many genes missing from the
17-gene signature for prediction analysis. The 14th dataset
GSE2514 in Table 1 that is a mouse gene expression data-
set was not applied to the diagram in Figure 1 and was not
included in calculating the accuracy of prediction in the
meta-analysis. In studies containing multiple probes from
a given gene symbol, one was randomly selected and sub-
ject to analyses.
Clustering analysis and evaluation of classification of lung 
cancer with miRNA target genes
Clustering of gene expression profiles used Gene Cluster
3.0, and the parameters used are the following: after
removing genes that had good data in less than 80% of
specimens examined, data were adjusted by gene center-
ing only (no array centering), and the hierarchical cluster-
ing used uncentered correlation as the similarity metric
and average linkage as the clustering method. Classifica-
tion of lung cancer specimens by miRNA target genes was
compared to the clustering profiles of mRNA expression
in the original article publishing the Database 1 [16]. Pre-
dicted target genes were categorized by biological process
ontology terms, and the one among the 4 categories with
the largest number of genes that has the most similar clus-
tering patterns to the mRNA expression profiles of the
specimens was chosen for the next step of class prediction;
AD and SCC subtypes were used for subsequent classifica-
tion by the gene expression signature because they are the
best classified by these genes among all the histologic sub-
types examined. For the detail why AD and SCC were
selected but not small cell lung carcinoma (SCLC) and
large cell lung carcinoma (LCLC), see below and Addi-
tional file 2 for detail.
Data adjustment and prediction of tumor subtypes
Because microarray datasets use different platforms and
the data are presented in different formats, the microarray
data were adjusted to similar scale and distribution pat-
terns before class prediction based on four guidelines (for
detail, see Additional file 2). First, for microarrays spotted
with cDNA clones presented with log2-transformed data,
no adjustment was made. Second, for data from oligonu-
cleotide-arrays (for example, Affymetrix) that has not
been log2-transformed, ratio of each data point to the
average expression of the 17 "core" genes across all speci-
mens was calculated, followed by log3-transformation,
because log3-transformed data have a better overlapped
distribution with the cDNA-spotted microarray data com-
pared to log2 transformation. To be consistent, data from
all oligonucleotide arrays were log3-transformed with a
few exceptions. For detail, see Additional file 2. Third, for
data from oligonucleotide-arrays that has been log2-trans-
formed, each data point was raised to the power of 2 and
re-log3-transformed. Fourth, for data from oligonucle-
otide-arrays in which their log-base is unknown or data
formats are unusual and therefore cannot be justified
using data distribution, a simple ratio between each data
point and the average expression was computed. Gene
expression was trained using Prediction Analysis of Micro-
arrays (PAM) Version 2.13 using the nearest shrunken
centroid algorithm [17]. Missing microarray data were
handled by the k-nearest neighbor imputation engine
using 10 nearest neighbors. When the 17-gene signature
was identified, expression data of these 17 genes (or any
A flow diagram outlines selection of 13 human lung cancer  databases used in this study Figure 1
A flow diagram outlines selection of 13 human lung 
cancer databases used in this study. This diagram does 
not include the 14th dataset GSE2514 in Table 1 that is a 
mouse gene expression dataset and was not used to calculate 
the accuracy of prediction in the meta-analysis. DB, database.BMC Medical Genomics 2008, 1:61 http://www.biomedcentral.com/1755-8794/1/61
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number of genes that are available in the selected data-
sets) were extracted. In the subsequent prediction analy-
sis, the Database 1 continues to serve as the training set,
and each one of the rest of datasets was the test set for pre-
diction. Since all 17 genes were used, the threshold was set
to 0 (used all genes) and follows the standard procedure
of PAM for the rest of steps without any modification
from the instruction. Significance Analysis of Microarrays
(SAM) was used to demonstrate the false detection rate for
separating AD from SCC in the Database 1 by the 17-gene
signature.
Results
Independent studies demonstrated reduced expression of 
miR-34b/34c in lung cancer
A search of miRNAs preferentially expressed in normal
lung in our previously published dataset found a group of
3 miRNAs (miR-34b, miR-34c, and miR-449) that had
approximately a thousand copies or less each cell in testes,
fallopian tubes, lung, and trachea, while the rest of tissues
examined had no or barely detectable levels of expression
[9] (Figure 2A). Lung-enriched expression of miR-34b/34c
was also observed in three other independent studies. In
one report expression of miR-34b and 34c were higher
than 7 other tissue types [8], while the other one showed
that precursor miR-34b and 34c expression was primarily
in lung and testis [18]. The third report did not have infor-
mation for miR-34c but showed increased expression of
miR-34b in lung [19]. The promoter regions of miR-34b/
34c genes have potential p53-binding sites that have been
experimentally verified, and both miRNAs are part of the
p53 tumor suppressor network [20]. Although miR-449
lacks such information as transcriptional regulation and
functional roles, a web-based tool [21] that identifies
potential cis-regulatory elements by comparative genom-
ics recognizes a p53-binding site within a region about 1.5
kb upstream to the miR-449 gene (see Additional file 2
and its Figure 1).
Two independent datasets were used to test the hypothesis
whether these miRNAs (miR-449 was not available in
these two databases) had reduced expression in lung can-
cer. One is from our previous published miRNA expres-
sion profiles in the NCI-60 panel of cell lines derived from
human cancers that used real-time PCR for quantitation
[22], and the expression of miR-34b and miR-34c in 9 cell
lines derived from lung was compared with that in normal
lung tissue obtained from our body map data [9] (Figure
3, and Addition file 2 and its Table 1). Expression of the
four miRNA sequences quantitated in this study (miR-
34b/34bN and miR-34c/34cN) in normal lung is from 90-
fold to over 1,300-fold higher than in any of the lung can-
cer cell lines tested (Figure 2B). Another dataset used a
bead-based technology to quantitate miRNAs [8], and the
expression of both miR-34b and miR-34c is again signifi-
cantly higher in normal lung than in 6 lung tumor speci-
mens (Figure 2C, p = 0.004 and 0.002, respectively, by t-
test). The same significant difference was observed
between normal mouse lung and tumor specimens from
lung tissues of mice carrying oncogenic K-ras [23] (Figure
2C). This echoes the observation made by a separate
group in which miR-34b expression was found decreased
by more than 90% in 4 out of 5 AD and 2 out of 8 SCC
[19].
Predicted target genes of miR-34b/34c/449 ontologically 
termed with developmental processes distinguish lung 
adenocarcinomas from squamous cell carcinomas
It has been shown that the union of miRNA target genes
predicted by three computational algorithms (miRanda,
PicTar, and TargetScan) is one of the strategies that give
the highest sensitivity [24], which predicted total 2414
unique gene symbols targeted by miR-34b/34c/449 (see
Additional file 3 for complete list of genes), and 2033 of
these genes were categorized in GO. The 4 largest catego-
ries in the biological process ontology term are signal
transduction (361 genes, 17.8%), nucleoside, nucleotide,
and nucleic acid metabolism (358 genes, 17.6%), and
developmental processes (251 genes, 12.3%). Protein
metabolism and modification (300 genes, 14.8%) consti-
tutes the third largest group but has a much higher p value
than the other 3 groups and therefore was excluded from
further analysis (see Additional File 2 and Additional file
4). Using the Stanford lung cancer dataset (Database 1 in
Table 1) [16] that contains four major subtypes of lung
cancer (AD, SCC, SCLC, and LCLC), unsupervised classifi-
cation of the specimens with genes from these three GO
categories was compared with the classification profiles
using the 918 cDNA clones selected by the authors in the
original article. This result suggests that the developmen-
tal process genes might better distinguish AD from SCC,
but not as well to classify SCLC and LCLC (see Additional
file 2 and its Figure 2). Using AD, SCLC, and LCLC speci-
mens from Database 6 [25] to train the 251 developmen-
tal process genes for predicting the four tumor subtypes in
Database 1 further supports the use of these genes to clas-
sify AD and SCC (see Additional file 2 and its Figure 3).
Expression of a 17-gene signature correctly predicts most 
lung adenocarcinomas and squamous cell carcinomas in 
independent datasets
The developmental process genes with eligible data points
in the Database 1 were re-analyzed by PAM as a training
set. After cross-validation, the error plot shows the lowest
error rate between threshold 0 and 1.6, indicating that the
genes represented by the threshold 1.6 is the minimal sub-
set of "core genes" that can best separate the 41 AD and 17
SCC in this dataset (which outputs the 17 genes). SAM
algorithm also showed that these 17 genes have the lowest
false detection rate to separate AD from SCC (q valueBMC Medical Genomics 2008, 1:61 http://www.biomedcentral.com/1755-8794/1/61
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Figure 2 (see legend on next page)BMC Medical Genomics 2008, 1:61 http://www.biomedcentral.com/1755-8794/1/61
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equals to 0). Examining the predicted target sites of miR-
34b/34c/449 in these 17 genes showed that most of the
genes have target sites predicted by at least 2 of the 3 algo-
rithms and at least 2 target sites predicted by at least one
of the algorithms (Table 2). Six of these 17 genes have
increased expression in all SCC, while 9 genes have higher
expression in at least a subset of AD than in normal lung
(Figure 2D). Expression of the other two genes, FOS and
TGFBR2, is reduced in tumor tissues, which is in agree-
ment with the literature [26-28]. Five out of the 17 genes
(CRABP2, CRIP2, FOS, JAG1, and MST1R) were among
the differentially expressed markers between AD and SCC
in the original report publishing the Database 1 [16]. Two
genes, BMP7 and JAG1, were also among the 23 genes that
had 4-fold or greater expression in SCC than in AD
reported in a separate paper [29].
Expression of the 17 core genes in another 8 validation
datasets [25,30-35] was used to predict the diagnosis of
specimens as AD or SCC. There are in total 313 AC and
265 SCC specimens, and the expression of the 17 genes
correctly predicted 79~100% of AD and 59~86% of SCC
(Figure 4). There are another 4 datasets [36-38] that have
fewer genes available for validation (14 to 16 genes, see
Table 1) and have 103 AD and 79 SCC specimens in total,
and still 70~100% of AD and 80~90% of SCC were cor-
rectly predicted (Figure 4).
The Database 14 contains 44 specimens derived from a
urethane-induced mouse lung tumor model in which the
neoplastic tissues exhibit histological appearance and
molecular changes similar to human lung AD [38]. This
dataset has only 13 of the 17 core genes available for anal-
ysis, and expression of these 13 genes can still correctly
predict all specimens as AD. Together with the 4 datasets
described above that had 14 to 16 of the 17 genes availa-
ble, this result suggests that at least some datasets need
only part of the 17 genes to distinguish AD from SCC, and
therefore there might be signaling pathway(s) represented
by genes from this signature underlies the unique biolo-
gies of these two subtypes.
The transforming growth factor-beta pathway is 
overrepresented in the 17-gene signature
The pathway ontology terms of the 17 genes shows that
only the TGF-beta signaling pathway is overrepresented
after Bonferroni correction (3 genes, p = 0.02, see Addi-
tional file 2 and its Table 2). At the beginning of analysis,
there were 29 genes out of the 2033 GO-termed genes that
belong to the TGF-beta pathway (versus 11.96 genes
expected, p = 0.011 by Fisher's exact test), and genes in
this category was further enriched such that 16 out of the
251 developmental process genes (versus 1.57 genes
expected, p = 0.00001 by Fisher's exact test) were in this
category. Therefore, the emergence of TGF-beta signaling
cascade does not appear to be a random event, but rather
a specific enrichment to suggest its central role in AD and
SCC.
Expression of BMP7, TGFBR2, and FOS was collectively
compared in all datasets except for the Database 5 that
had only SCC available. Among the 11 datasets, majority
of them show that BMP7 is up-regulated and TGFBR2/
FOS are down-regulated in both AD and SCC compared to
normal lung, whereas between AD and SCC, BMP7 has an
opposite expression pattern to TGFBR2/FOS (Figure 5).
These results support that both AD and SCC subtypes
have suppressed TGF-beta signaling but through different
mechanisms: in SCC there is increased expression of
BMP7 that antagonizes TGF-beta functions [39], and
reduced expression of TGFBR2, which suggests that SCC
might be more sensitive than AD to targeting BMP7 or
increasing expression of TGFBR2. An additional analysis
of another TGF-beta inhibitory molecule SMAD7 [40]
that is not in the final 17-gene signature but in the 251
developmental process genes is also consistent with these
results (see Additional file 2 and its Table 3).
Several randomized controls were used to compare with
the process of identification of this 17-gene signature.
Three miRNAs, miR-141/146b/216, were randomly cho-
sen and all subsequently procedures followed the same
workflow for the miR-34b/34c/449 including prediction
of targets, screening of gene symbols and GO categories/
A, expression of miR-34b/34c/449 is enriched in normal lung, fallopian tube, and testis Figure 2 (see previous page)
A, expression of miR-34b/34c/449 is enriched in normal lung, fallopian tube, and testis. CT higher than 35 is gener-
ally considered as less reliable, and equals to around 5 copies of miRNA. Dashed line: around 20 copies of miRNA. Expression 
of these 3 miRNAs is much higher than this line in lung, fallopian tube, and testis than in the rest of tissues examined. B, expres-
sion of miR-34b/34c/449 is reduced in the 9 lung cancer cell lines of the NCI-60 panel compared to normal lung, represented 
by ΔCT (tumor cell line – normal lung). C, expression of miR-34b/34c is reduced in both human and mouse primary lung cancer 
tissues compared to normal lung. The log2-based background fluorescence intensity is between 5 and 6, so tumor lung and 
non-lung normal human tissues have essentially no miR-34b expression and some minimally detectable miR-34c, consistent 
with the TaqMan®-based results in the panel A. D, expression of the 17 "core" genes in specimens from the Database 1; blue 
bar, genes with higher expression in SCC; red bar, genes with higher expression in AD; *, two genes with higher expression in 
normal lung; scale bar represents fold change while gray in the heat map indicates missing data.BMC Medical Genomics 2008, 1:61 http://www.biomedcentral.com/1755-8794/1/61
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A similarity metric demonstrates the correlation of miR-34b/34c expression between lung cancer cell lines (blue letters) Figure 3
A similarity metric demonstrates the correlation of miR-34b/34c expression between lung cancer cell lines 
(blue letters). All NSCLC cell lines are in the blue bracket, suggesting that expression of miR-34b/34c/449 might be candi-
dates to classify different types of lung cancer. The calculation of the distance matrix was based on the ΔCT (the average CT of 
miR-34b/34bN/34c/34cN between two cell lines), so the smaller the ΔCT, the more similar expression levels of the four 
miRNA sequences are in the two cell lines (more red in the heat map).BMC Medical Genomics 2008, 1:61 http://www.biomedcentral.com/1755-8794/1/61
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terms, union of all selected genes, and clustering analysis
of tumor specimens. Two random sets of 17 genes were
also selected to use the Database 1 as the training set and
predict AD/SCC in the Database 2. Classification and pre-
diction of AD and SCC subtypes using the miR-34b/34c/
449 prediction targets and the 17-gene signature, respec-
tively, are clearly better than randomized controls. Detail
of these analyses and selected genes are described in Addi-
tional files 2 and 5.
Expression of the "core" gene signature has the potential 
to diagnose lung cancer using bronchoscopic specimens of 
cigarette smokers
The possibility of using this gene signature for early detec-
tion of lung cancer and predict tumor subtypes was evalu-
ated using a published microarray dataset of large-airway
epithelium taken by bronchoscopy from cigarette smok-
ers with suspicion of lung cancer [7]. With 16 of the 17
genes available in the dataset, the signature cannot distin-
guish whether the tumor types of the patients were AD or
SCC (data not shown). However, these 16 markers are dif-
ferentially expressed in the specimens between smokers
diagnosed with (N = 59) and without (N = 69) lung can-
cer (Figure 6). Using their expression as a training set to
cross-validate the diagnosis demonstrated 73% sensitivity
and 77% specificity, and testing the prediction on an inde-
pendent dataset (18 cancer and 17 non-cancer cases)
showed similar 78% sensitivity and 65% specificity (Fig-
ure 7, Additional files 6 and 7). The predicting power of
these 16 markers approaches that of the 80-probe biomar-
ker identified in the original paper publishing the datasets
(80 to 83% in sensitivity) but far better than that of bron-
choscopy diagnosis by cytopathology alone (44 to 53% in
sensitivity) [7]. Combining both cytopathology and
expression of the 16 markers of the epithelial cells from
the training and the validation sets yielded 90% and 89%
sensitivity to detect patients with lung cancers, respec-
tively (Figure 7). Again, this also comes near to the origi-
nal report's 80-gene marker when combining with
cytopathology of the cells (95 and 94%, respectively) [7].
However, because the 80-gene marker cannot predict lung
cancer subtypes, and cannot distinguish tumors from
their adjacent normal tissues [7], the 17 markers identi-
fied here might be proven to be more valuable in future
diagnostic tests.
Discussion
There have been a number of studies to directly profile
miRNA expression in lung cancers, and unique groups of
miRNAs were identified to either characterize the neoplas-
tic tissues or mark patients with poor prognosis [41-43].
This study followed a different rationale to start with three
miRNAs enriched in lung but reduced in lung cancers.
Since genes targeted by miRNAs determine the final bio-
logical activities of these miRNAs, miR-34b/34c/449 is
likely to regulate expression of lung cancer markers that
might define certain phenotypes of this tumor. Such a
rationale transcends the search of predicted target genes
with reversed correlation in expression following a
miRNA expression profiling, in which any target genes
regulated by miRNAs at their protein, not mRNA, levels
would have been missed otherwise. Computational pre-
Table 2: The frequency of predicted miR-34b/34c/449 target sites within the 17 core genes
Algorithm TargetScan 4.0 MiRanda v4 PicTar
miRNA 34b (c*) 34b (pc**) 34/449 (c*) 34/449 (pc**) 34b 34c 449 34b 34c
BMP7 1 1
CRABP2§ 12 1
CRIP2§ 11 1
EFNB1 1 1 2 1 1
FLII 11
FOS§ 11
JAG1§ 11 1 1 1 1
MST1R§ 1
MUC5B 12
NR4A2 1 1 22
NRG1 13 3
RELN 1 1
TGFBR2 2 1 1 1
THBS3 22
TLE2 1 1
TPM2 2
VAMP2 1 1 3 1 1
*c: Conserved sites for miRNA families conserved in human, mouse, rat, and dog.
**pc: Poorly conserved sites and sites for poorly conserved miRNA families.
§Genes also reported as differentially expressed between AD and SCC in the paper that published the Database 1.BMC Medical Genomics 2008, 1:61 http://www.biomedcentral.com/1755-8794/1/61
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dictions of miRNA target genes, followed by a series of
data filtering using representation of GO terms and classi-
fication of lung cancer specimens, point to a minimal set
of 17 genes derived from 251 developmental process
genes that correctly predict most of AD and SCC tumors
selected from multiple independent cohorts. This gene
signature probably represents the least but definitely not
the most of miR-34b/34c/449-target genes that participate
in tumorigenesis of lung cancer, but the data have sug-
gested the significance of the TGF-beta pathway in these
two lung cancer subtypes for future validation and cer-
tainly deserves further investigation.
Although miR-34a was initially identified having tumor-
suppressing activity together with miR-34b/34c [20], miR-
34a is rather ubiquitously expressed in most human tis-
sues and not enriched in lung [9]; yet, this does not
exclude the possibility of miR-34a involving in lung can-
cer tumorigenesis. It might be important to appreciate the
fact that miR-34b/34c are expressed in several organs
(such as ovary) in additional to lung (unpublished data)
in mice, and that whether roles of these two miRNAs
underlying lung AD and SCC would be different between
human and rodents, since animal models might be used
in the future to evaluate the activities of miR-34b/34c/
The test probabilities (Y-axis) of predicting AD and SCC specimens from 14 published datasets using the 17 "core" genes Figure 4
The test probabilities (Y-axis) of predicting AD and SCC specimens from 14 published datasets using the 17 
"core" genes. Group 1, AD; group 2, SCC; black circle, predicted as AD; red circle, predicted as SCC.BMC Medical Genomics 2008, 1:61 http://www.biomedcentral.com/1755-8794/1/61
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Expression of BMP7, TGFBR2, and FOS was examined in AD, SCC, and normal lung from 12 of the 13 human gene expression  databases Figure 5
Expression of BMP7, TGFBR2, and FOS was examined in AD, SCC, and normal lung from 12 of the 13 human 
gene expression databases. Each circle represents the average expression of all specimens from the same tumor subtype 
using the original data format and scale. "NA", not available for analysis due to missing data. Gray shaded boxes indicate the rel-
ative expression levels of the genes are not coherent to the expected patterns.BMC Medical Genomics 2008, 1:61 http://www.biomedcentral.com/1755-8794/1/61
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449. It is imperative to recognize that (1) expression of
miR-34b/34c/449 in normal tissues is lung-enriched and
is reduced in lung cancer in general, whereas many other
non-lung-enriched miRNAs could be also greatly differen-
tially expressed between normal and cancerous lung tis-
sues, (2) the predicted miR-34b/34c/449 targets from the
developmental process GO term classify AD and SCC bet-
ter than the predicted targets from other tested GO catego-
ries, whereas many other miRNAs and their target genes
could be also differentially expressed between AD and
SCC, and (3) the 17-gene signature is the final chosen pre-
dictor based on their best SAM false detection rate,
whereas all 153 genes (the number of genes with eligible
data points in Database 1 only) also gave the same predic-
tion error rate as the 17 core genes did. Therefore, it does
not preclude the roles of other miR-34b/34c/449 targets,
and other miRNAs and their targets. Accordingly, rand-
omized controls, instead of permutation of all available
miRNAs/target genes, were taken to ensure the quality of
the data, for example, 17 genes were randomly selected
from GO categories other than the developmental process
term but not from inside the developmental process cate-
gory.
AD is a collection of heterogeneous tumors with a variety
of histologies. For example, as reported previously, AD
specimens from the Databases 1, 2, and 3 containing
higher percentage of poorly differentiated tumor cells
tend to have similar molecular characteristics to SCC and
LCLC (namely "squamoid" and "magnoid", respectively),
while tumors with a more differentiated phenotype
resemble bronchioalveolar carcinoma ("bronchioid") [4].
Staging of the tumors in all the databases analyzed in this
study also varies significantly (Table 1). However, expres-
sion of the 17 core genes does not seem to associate with
these factors, suggesting that this gene expression signa-
ture might be independent of histologic features of AD
and SCC, degree of differentiation, and progression of dis-
ease, and might represent fundamental biologies of the
subtypes, such as cellular origins.
This paper embarks a genome-scale meta-analysis strategy
that has at least three advantages compared to either a
direct profiling of miRNAs in lung cancers or a direct iden-
tifying differentially expressed mRNAs in AD and SCC.
First, this strategy provides more insights on mechanisms,
applications, and functions in connection to the his-
topathological characteristics underlying AD and SCC of
lung. The gene expression signature was identified based
on their being predicted targets of three lung-enriched
miRNAs, opening the possibility that their expression in
vivo might be subject to regulation by these miRNAs, and
that delivery of these miRNAs might be able to modulate
tumorigenic phenotypes, such as TGF-beta pathways that
is over-represented in the identified gene signature. Sec-
ondly, identifying differentially expressed genes often fol-
Differential expression of the 16-gene signature in the specimens from cigarette smokers diagnosed with (N = 59, red bar) and  without (N = 69, blue bar) lung cancer in the training set Figure 6
Differential expression of the 16-gene signature in the specimens from cigarette smokers diagnosed with (N = 
59, red bar) and without (N = 69, blue bar) lung cancer in the training set. The scale bar represents the difference of 
Robust Multichip Average-generated expression value between each data point and the average expression value for each 
gene.BMC Medical Genomics 2008, 1:61 http://www.biomedcentral.com/1755-8794/1/61
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Diagnostic evaluation of two microarray datasets of bronchoscopic specimens using expression of the 16-gene signature alone,  and combination of gene expression and cytopathology Figure 7
Diagnostic evaluation of two microarray datasets of bronchoscopic specimens using expression of the 16-gene 
signature alone, and combination of gene expression and cytopathology. GE+ and GE-, predicted as cancer and non-
cancer by the signature, respectively. Bronch+ and Bronch-, cancer and non-cancer diagnosis by cytopathology examination. 
PPV and NPV, positive predictive value and negative predictive value, respectively.BMC Medical Genomics 2008, 1:61 http://www.biomedcentral.com/1755-8794/1/61
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lows data filtering, which only hones in the most variable
expression between the groups, and apparently will dis-
count genes whose differential expression is under the
threshold but might be better candidate markers. In fact,
several genes in the signature were also identified as differ-
entially expressed between AD and SCC previously (for
example, genes that are marked with § in Table 2). Finally,
this study avoids identifying predicted target genes whose
expression patterns are opposite to those of the miRNAs,
but rather depends on their ability to classify the tumor
subtypes of interest, especially when no such collection of
datasets for miRNA expression available in short term
comparable to the size of mRNA expression cohorts used
in this study.
Identification of the potential significance of targeting
TGF-beta pathways in AD and SCC mirrors previous
reports on roles of reduced TGF-beta signaling in lung
cancer tumorigenesis [26,27]. Another TGF-beta inhibi-
tory molecule SMAD7 [40] in the 16 TGF-beta pathway
genes from the 251 developmental process genes has
increased expression in AD than in SCC in all but one
datasets (see Additional file 2), which supports the notion
that distinctive mechanisms might be used by AD and
SCC to suppress TGF-beta pathways.
Despite their differential expression among AD, SCC, and
normal lung tissues, the 17-gene signature has no differ-
ence in expression in the airway epithelial cells taken from
smokers diagnosed with AD or SCC, and most genes had
reduced expression in the bronchoscopic specimens from
patients with lung cancer, with a few exceptions such as
FOS gene (Figure 6). Consistent with the clustering pat-
terns of the Database 1 using this signature in which SCLC
was well separate from the other three subtypes (Figure
2D), 6 of 16 cancer cases in the training set predicted as
non-cancer are SCLC, compared to only 5 SCLC in 44 pre-
dicted positive cases (p = 0.03 by Fisher's exact test).
Apparent lower specificity of prediction by this signature
in the validation set parallels an interesting pattern of
probability distribution in the training set, in which more
recent cases seem to have higher probability of being pre-
dicted as cancer, suggesting that the follow-up time might
not be long enough (see Additional file 2 and its Figure 8
for further discussion). The gene signature identified here
can distinguish lung cancer cells from normal lung as well
as their peripheral normal tissues (Figure 2D), whereas
the markers identified in the article that published the
bronchoscopy specimens datasets cannot (although it
appeared that the 80-gene signature in the original report
can distinguish tumors from normal lung from separate
individuals) [7]. It warrants future investigation of a pos-
sible two-step diagnostic procedure for cigarette smokers:
large-airway epithelial cells obtained by bronchoscopy are
examined by both cytopathology and expression of the
17-gene signature, if the subject is predicted as positive
and the cancer diagnosis is further confirmed, followed by
examining the expression of the same signature in tumor
tissues for classification as AD or SCC. Due to the strong
association of cigarette smoking with lung cancer and sig-
nificant false-positive/false-negative rates of lung cancer
detection by computed tomography, the findings may sig-
nificantly impact both basic research and clinical manage-
ment of lung cancer.
Conclusion
This study followed an in silico strategy to first compile a
largest possible list of miRNA targets predicted by multi-
ple algorithms, which was subsequently filtered by GO
terms and their enriched representation, and their ability
to classify different subtypes of lung cancer. This led to the
focus on a list of genes that belongs to the developmental
process GO term. Selecting from a final 17-gene expres-
sion signature that has the best false detection rate cor-
rectly predicts the majority of the AD and SCC subtypes of
lung cancer when compared to the histological diagnosis.
Most importantly, expression of the same signature in
bronchial epithelial cells from cigarette smokers can dif-
ferentiate whether the patients have lung cancer or not
when combined with the cytopathology of the bronchial
cells. The results not only provide a functional basis for
regulating expression of the markers, but also suggest a
two-step diagnostic procedure to smokers: the first step is
to combine cytology and expression of the 17-gene signa-
ture in large-airway epithelial cells by bronchoscopy; if the
subject is predicted as positive and the cancer diagnosis is
confirmed, the second step is to classify the tumor as AD
or SCC by examining the expression of the same signature
in resected or biopsied tumor tissues.
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